Ximelagatran was generally well tolerated in the trial populations .
A small proportion ( 5 - 6 % ) developed elevated liver enzyme levels , which prompted the FDA to reject an initial application for approval in 2004 .
Ximelagatran was generally well tolerated in the trial populations , but a small proportion ( 5 - 6 % ) developed elevated liver enzyme levels , which prompted the FDA to reject an initial application for approval in 2004 .